[[3, 6, 765, 38, "Table 3. 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine"], [1, 47, 187, 74, "Substitutions"], [388, 287, 407, 320, "ZI"], [449, 287, 469, 320, "ZI"], [449, 361, 520, 389, "IL-1"], [625, 357, 710, 392, "cLogP"], [25, 375, 158, 406, "Compound"], [253, 372, 296, 408, "R3"], [761, 373, 831, 405, "LLEd"], [420, 390, 547, 424, "1C50(M)c"], [628, 392, 710, 420, "cLogD"], [25, 451, 156, 476, "GDC-2394"], [262, 453, 288, 476, "H"], [395, 449, 571, 479, "0.0054  0.004"], [648, 451, 690, 479, "1.1"], [256, 464, 292, 494, ".N."], [775, 467, 817, 493, "8.2"], [64, 483, 117, 513, "(20)"], [441, 484, 525, 516, "(n=16)"], [647, 481, 690, 512, "0.1"], [649, 563, 688, 590, "1.1"], [60, 579, 122, 607, "R-20"], [458, 577, 512, 607, "1.40"], [774, 577, 818, 607, "5.8"], [647, 594, 690, 625, "0.1"], [403, 676, 563, 703, "0.013  0.008"], [647, 673, 691, 703, "1.6"], [67, 690, 114, 719, "21a"], [776, 691, 818, 719, "7.5"], [449, 709, 520, 741, "(n=3)"], [647, 707, 691, 736, "0.4"], [206, 766, 264, 789, "MeO"], [410, 789, 555, 814, "0.012  0.01"], [647, 786, 691, 817, "1.2"], [67, 803, 113, 832, "22a"], [774, 803, 818, 832, "7.8"], [450, 821, 520, 854, "(n=3)"], [648, 821, 690, 849, "0.1"], [647, 899, 693, 928, "1.7"], [67, 914, 113, 944, "23b"], [455, 915, 512, 944, "2.40"], [774, 915, 818, 945, "5.7"], [644, 932, 694, 961, "-0.1"], [0, 1000, 852, 1042, "'Data reported for the most potent stereoisomer. bTested as the"], [1, 1042, 850, 1075, "racemate. 'Inhibition of the NLRP3 inflammasome pathway was"], [3, 1082, 851, 1111, "assessed by quantifying IL-1 release from LPS + nigericin stimulated"], [3, 1115, 850, 1146, "hPBMCs (reported as geometric mean  SD; compounds R-20 and"], [0, 1144, 853, 1187, "23 are reported as n = 1). dLLE was calculated using the following"], [5, 1185, 497, 1218, "equation: LLE = pICso IL-1 - cLogD."]]